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Abstract Worldwide, there are more than 10 million
new cancer cases each year, and cancer is the cause of
approximately 12% of all deaths. Given this, a large
number of epidemiologic studies have been under-
taken to identify potential risk factors for cancer,
amongst which the association with trace elements has
received considerable attention. Trace elements, such
as selenium, zinc, arsenic, cadmium, and nickel, are
found naturally in the environment, and human
exposure derives from a variety of sources, including
air, drinking water, and food. Trace elements are of
particular interest given that the levels of exposure to
them are potentially modifiable. In this review, we
focus largely on the association between each of the
trace elements noted above and risk of cancers of the
lung, breast, colorectum, prostate, urinary bladder,
and stomach. Overall, the evidence currently available
appears to support an inverse association between
selenium exposure and prostate cancer risk, and
possibly also a reduction in risk with respect to lung
cancer, although additional prospective studies are
needed. There is also limited evidence for an inverse
association between zinc and breast cancer, and again,
prospective studies are needed to confirm this. Most
studies have reported no association between sele-
nium and risk of breast, colorectal, and stomach
cancer, and between zinc and prostate cancer risk.
There is compelling evidence in support of positive
associations between arsenic and risk of both lung and
bladder cancers, and between cadmium and lung
cancer risk.
Keywords Trace elements Æ Selenium Æ Zinc Æ
Arsenic Æ Cadmium Æ Nickel Æ Neoplasms
Abbreviations
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ICP-MS inductively coupled plasma mass
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Cancer
NAA neutron activation analysis
Ni nickel
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ppb part per billion
Se selenium
SIR standardized incidence ratio
SMR standardized mortality ratio
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Prevention Trial
ATSDR United States Department of Health and
Human Services Agency for Toxic
Substances & Disease Registry
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Introduction
There were an estimated 10.9 million new cancer cases
and 6.7 million cancer deaths worldwide in 2002 [1]. Of
these, cancers of the lung, breast, colorectum, and
stomach were the most common [1]. Additionally,
prostate cancer was the fifth most common cancer
overall and the second most common among men, and
bladder cancer, ranked ninth in terms of incidence, was
more common in developed countries (63% of all new
bladder cancer cases) and among men (77% of new
bladder cancer cases occur in men) [1]. Given the
burden of disease associated with these cancers, a large
number of epidemiologic studies have been under-
taken to identify potential risk factors. Amongst the
many factors that have been explored, the association
with trace elements has received considerable atten-
tion. Trace elements are of particular interest given
that levels of exposure to them are potentially
modifiable.
The term ‘trace element’ refers to chemical elements
present or required in minute quantities. Trace elements
are found naturally in the environment and human
exposure derives from a variety of sources, including air,
drinking water, and food (Table 1). The World Health
Organization has classified 19 trace elements as being
important to human health, including arsenic (As),
cadmium (Cd), nickel (Ni), selenium (Se), and zinc (Zn),
amongst others (Table 1) [2].
There is a large body of literature on the role of
trace elements in the development of cancer. Arsenic
exposure has been examined in relation to cancer risk,
generally focusing on exposure via drinking water. In
addition, a number of studies of Cd, and Ni have been
conducted, with a primary focus on work-place expo-
sures. Finally, there is substantial interest in the role of
Se and Zn with respect to a number of cancer sites.
While Se tends to be inversely associated with cancer
risk [3, 4], Zn appears to be protective when Zn defi-
cient individuals are compared to those who are Zn
sufficient [5], whereas it appears harmful when those
who have Zn overload as a result of environmental
exposure are compared to those who are Zn sufficient
[6]. Cd, Ni, and As are generally associated with in-
creased risk of many cancers [7] and each of them has
been designated as a Group 1 human carcinogen by the
International Agency for Research on Cancer (IARC)
[8–10] and the US National Toxicology Program.
In this review, we focus on the association between
each of the trace elements noted above and risk of
cancers of the lung, breast, colorectum, prostate, uri-
nary bladder, and stomach, the anatomical sites that
have been studied most commonly. We precede our
review of the epidemiologic literature with a brief
discussion of the sources of exposure to trace elements,
methods for measuring trace element exposure, and




We aimed to identify all epidemiologic evidence relevant
to the research question. Therefore, epidemiologic
literature regarding trace element exposure and risk of
cancers of the breast, lung, colorectum, prostate,
bladder, and stomach, was searched for, obtained, and
reviewed.
A systematic search of Medline (1966-present) was
carried out for the relevant epidemiologic literature. In
Table 1 Average exposure to trace elements from common sources
Trace elementa Average exposure by source
Water (/day)b Diet (/day) Air (/m3)
Arsenic <1 ng–7200 lg, depending on
geographic locale [11, 14, 16]
50 lg–200 lg (3.5 lg of
inorganic arsenic) [2, 11]
1–2000 ng [11, 12]
Cadmium 0.01–0.2 lg (50 lg in heavily
polluted areas) [13, 14]
3 lg–160 lg, approximately
1–3 lg is absorbed [13, 14]
1–40 ng [13, 14]
Nickel 10–20 lg (up to 200 lg in
mining areas) [14, 15]
8 lg–170 lg, < 2% is absorbed [14, 15] 7–12 ng [14, 15]
Selenium <1 lg–300 lg [18] 71–152 lg [2, 18]c Not a common source
of exposure
Zinc Varies depending on
zinc content of pipes
5.2–16.2 mg [2, 17] 0.1–1.7 lg [17]
a Source: World Health Organization. Trace elements in human nutrition and health. Geneva: World Health Organization, 1996
b Assuming an intake of 2 l water/day
c Varies depending on soil concentrations in which foods were grown
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addition, we followed-up on references from relevant
papers and prior reviews of trace elements. Appendi-
ces 1 and 2 show the search strategy employed for each
of the cancers and trace elements in Medline.
Study selection
Epidemiologic studies of men and women were in-
cluded in this review. Each of the articles reviewed
reported on the effect of exposure to at least one of the
trace elements listed in Table 1 and reported on the
incidence, prevalence, and/or death from lung, bladder,
breast, colorectal, prostate, or stomach cancer. Epi-
demiologic studies not published in English were
excluded from this review, as were published abstracts
and non-peer-reviewed literature.
Data extraction and analysis
All relevant epidemiologic studies were read in full and
the data were extracted. Details on study design, study
population, exposure source and exposure measures,
outcome, results, and conclusions were recorded. In-
cluded studies were summarized in Tables 3–8 and
described briefly in the text. We considered issues re-
lated to exposure measurement, along with consider-
ations of study design, sample size, and magnitude of
effect, in drawing conclusions from the literature.
Sources of trace element exposure
Trace elements are found naturally in the environment
and human exposure derives from a variety of sources,
including air, drinking water, and food.
Concentrations of trace elements in the air are
generally low. Levels of As in the air range from
approximately 1 to 2,000 ng/m3 [11, 12], levels of Cd
generally range from 1 to 40 ng/m3 [13] but can reach
up to 100 ng/m3 near emission sources [14], and levels
of Ni in cities and rural areas range from 7 to 12 ng/m3
[15] (Table 1). Welders, workers in the smelting and
refining industries, and those employed in the
production of batteries, coatings, and plastics, can be
exposed to much higher levels of airborne Cd and Ni
[14, 15].
Each of the trace elements under consideration here
is found in drinking water supplies. The average
amount of Cd in drinking water is approximately 1 part
per billion (ppb) and intakes from drinking water range
from 0.01 lg/day in more remote geographic locations
to 25 lg/day in heavily polluted areas [14]. The average
concentration of Ni in water ranges from 3 to 7 ppb
[14, 15]. With respect to As, which is found naturally in
ground water, the Agency for Toxic Substances and
Disease Registry (ATSDR) in the United States esti-
mates that 80% of the US water supply has less than
2 ppb, but about 2% has greater than 20 ppb [11].
Internationally, levels of As in water range from as low
as <1 ng/m3 in remote locations (e.g., the Canadian
arctic) to as high as 2,000–3,600 lg/l in Bangladesh and
India [14, 16].
Diet is the primary source of Zn and a major source
of Se exposure. Average Zn consumption from food
ranges from 5.2 to 16.2 mg/day [14, 17] and Zn levels in
animal products vary depending on the soil and water
concentrations where the animals were raised [17].
Average Se consumption from food ranges from 71 to
152 lg/day [18]. Fish and seafood are the main sources
of dietary As exposure [11]. However, the As in these
foods is mainly in the form of organic As, which is
considered less harmful than inorganic As [11]. With
respect to Cd, the average individual consumes 30 lg/
day, but only 1–3 lg/day is absorbed into the body [13,
14]. Likewise, while average Ni consumption from
foods is 170 lg/day in the United States [15] and be-
tween 200 and 300 lg/day internationally [14], less than
2% is absorbed [15].
Methods for measuring trace element exposure
Exposure to many trace elements (e.g., As, Cd, and Ni)
is largely from occupational sources. Studies of
exposure to such trace elements have utilized various
exposure assessment methods including job histories
Table 2 Analytical methods
for measuring trace element
exposure in biological
specimens
Method Elements commonly tested
Atomic absorption spectrophotometry (AAS) Arsenic, Cadmium, Nickel, Zinc
Atomic emission spectroscopy (AES) Cadmium, Nickel
Inductively coupled plasma mass spectrometry
(ICP-MS)
Cadmium, Arsenic, Zinc, Selenium, Nickel
Neutron activation analysis (NAA) Arsenic, Cadmium, Nickel, Selenium
Fluorometry Arsenic, Zinc, Selenium
Cancer Causes Control (2007) 18:7–27 9
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(yielding subjective assessments of exposure as high,
medium, or low), measurement of airborne and static
dust, and personal monitoring devices. Often, these
measures are combined with job history information,
such as the number of years employed in a particular
area, to develop an estimate of cumulative exposure.
Between-study differences in the method of exposure
assessment make it difficult to compare results across
studies. Further, assessments based on type of
employment (e.g., production versus maintenance)









Exposure Comparison Risk estimate
(95% CI)
Lung
Chen et al. [37] Case–
control
444 (79) Taiwan Years of water
consumption





571 (152) Chile Water–As concentrations
from 1950 to 1994—
lifetime residential exposure




Chiou et al. [39] Cohort 2,556 (27) Taiwan Cumulative exposure
to As in drinking water
20+ vs. 0 mg/l · years RR = 4.01 (1.00–16.12)
Lewis et al. [41] Cohort 4,058 (34)a United
States




Chen et al. [40] Cohort 65,876a Bangladesh Drinking waterc ‡ 599 vs < 50 lg/l RRmen = 4.22
RRwomen = 9.00
Bladder
Chen et al. [37] Case–
control
444 (79) Taiwan Years of water
consumption
> 40 vs. 0 years OR = 4.10
Bates et al. [42] Case–
control
128 (114) Argentina Drinking waterb >200 vs. 0–50 lg/l OR = 0.60 (0.2–1.7)
years of well-
water use




OR smokers = 2.54
(1.0–6.4)
Chiou et al. [39] Cohort 2,556 (29) Taiwan Cumulative exposure to
As in drinking water
20+ vs. 0 mg/l · year RR = 3.58 (1.05–12.19)
Kurttio et al. [44] Case-
cohort
336 (61) Finland Cumulative exposure to
As in drinking water
> 2.0 mg vs. < 0.05 mg RRshort latency = 1.50
(0.71–3.15)d
RRlong latency = 0.53
(0.25– 1.10)
Lewis et al. [41] Cohort 4,058 (5)a United
States




Chen et al. [40] Cohort 65,876a Bangladesh Drinking waterc ‡ 599 vs < 50 lg/l RRmen = 16.87
RRwomen = 25.79
Chiou et al. [43] Cohort 4,074 (10) Taiwan Drinking waterb Arseniasis-endemic
area vs. general
population
SIR = 1.96 (0.94–3.61)
Stomach
Lewis et al. [41] Cohort 4,058 (19)a United
States





Lewis et al. [41] Cohort 4,058 (50)a United
States
Drinking water General population SMR = 1.45
(1.07– 1.91)
a Number in parentheses represents number of deaths; b As determined using atomic absorption spectroscopy (AAS); c Method of
determining As content of water not provided; d Statistically significant dose–response relationship reported; SMR = standardized
mortality ratio; SIR = standardized incidence ratio
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assume that emissions are confined to specific loca-
tions, which may not always be the case. In addition,
many of the occupational studies have (of necessity)
relied on historical data, which are limited due to
possible changes in production techniques and venti-
lation systems over time.
Several other methods for measuring trace element
exposure have been tested and utilized, including
assessment of dietary intake and analytical assessment
of trace element levels in biological and environmental
samples. Methods to assess intake of trace elements
from dietary sources (and via supplement use) include
24-h and 7-day dietary recalls, diet histories, and food
frequency questionnaires (FFQ) [19]. To date, these
methods have been used mostly to estimate dietary
intake of Zn and Se. Diet measurement methods are
limited due to the possibility of recall bias (particularly
in case–control studies), by the possibility of misclas-
sification of exposure due to the inherent inaccuracy of
such methods (for example, Se intake is measured
inaccurately by food frequency questionnaires [20]),
due to potential differences in absorption of trace
elements depending upon food preparation methods,
and due to variation by geographic locale in the levels
of trace elements in the soil in which foods are grown
[21]. However, this is less of an issue in developed
countries where most people do not eat locally grown
produce.
The various analytical methods for measuring
the content of trace elements in biological and
environmental samples are listed in Table 2. It
should be noted that the ability of each of these
methods to detect trace elements in biological
specimens is dependent, in large part, on the
specimen (e.g., blood, urine, hair, or nail), the
methods used to prepare the specimen for analysis,
and the trace element of interest [22]. A com-
prehensive discussion of the methods utilized for
each trace element is beyond the scope of the
present review—more information (described under
the ToxFaq for each trace element) can be found
at the United States Department of Health and
Human Services ATSDR website http://www.atsdr.
cdc.gov/toxfaq.html.
Table 4 Summary of epidemiologic studies of low level arsenic exposure (< 100 lg/l) and cancer risk












892 (433) USA Toenail b >0.139 vs.
< 0.059 lg/g




Case–control 1,778 UK Job records Exposed vs.
unexposed
OR = 1.1 (0.8–1.5)
Pershagen,
[46]




OR residents = 2.0 (1.2–3.4)
OR miners = 4.1 (1.7–9.7)
OR smelter workers = 3.0 (2.0–4.7)
Hazelton
et al. [47]





AR = 15.8% As alone
AR = 11% As & radon




Cohort 1,393 (23)a USA Job records General
population




Case–control 231 (71) Utah, USA Drinking waterc ‡ 75 vs. < 19 mg
(cum. dose)
OR = 1.41 (0.7–2.9)
‡ 74 vs. < 33 mg/l
· years
OR = 1.00 (0.5–2.1)
Steinmaus
et al. [51]
Case–control 509 (181) Western USA Drinking waterd > 80 vs £ 80 lg/d OR = 0.94 (0.56–1.57)
OR exposure > 40 years ago,





573 (280) Finland Toenailb > 0.161 vs. <
0.050 lg/g
OR = 1.13 (0.70–1.81)
a Number in parentheses represents number of deaths; b As content determined using Neutron Activation Analysis (NAA); c As
determined using X-ray emission spectroscopy; d As exposure based on Nevada State Health Division and California Department of
Health Services measures of community-supplied drinking water; AR = attributable risk; SMR = standardized mortality ratio
Cancer Causes Control (2007) 18:7–27 11
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Use of biological specimens for measuring trace
element exposure
Estimates of trace element exposure are often deter-
mined by sampling biological specimens such as blood
(including whole blood, serum, plasma, and erythro-
cytes), urine, hair, and nails, each of which differs in
terms of the exposure period represented. In relation
to the etiology of cancer, cumulative exposure is usu-
ally of interest. Plasma and serum measures tend to
reflect short-term exposures, while trace element levels
in erythrocytes represent long-term exposure [23].
Toenails are often preferable to other biological sam-
ples (e.g., blood, urine) for the measurement of trace
element levels because they reflect longer-term expo-
sure. A number of studies have assessed the validity/
reproducibility of toenails as a surrogate measure of
selenium intake [20, 24–26] and have shown good or
strong correlations between toenail measures and
intake. Although analytical methods for determining
Table 5 Summary of epidemiologic studies of cadmium (Cd) and cancer risk










Cohort 292 (12)a USA Job history General
population
SMRb = 235 (p = 0.05)
Sorahan
et al. [60]
Cohort 3,025 (89) UK Job history (Ni–Cd) General
population




Cohort 522 (195)a Sweden Job history (Ni–Cd) General
population
SMR = No association
Sorahan
et al. [62]





SMR = 130 (p < 0.01)
‡ 15 vs. 0 yrs RR = 1.5 (p = ns)
Kazantzis
et al. [63]
Cohort 7,000 (277)a UK Occupational exposure General
population
SMR = 115 (101–129)
Stayner
et al. [64]
Cohort 606 (24)a USA Job history General
population
SMR = 149 (95–222)
SMR among highest
exposure group = 272
(123–513)
Sorahan [65] Cohort 1,492 (92) UK Job history (Ni–Cd) General
population
SMR alloy workers = 101
(p = ns)
SMR vicinity workers = 160
(p < 0.01)
SMR brass/iron foundry




Cohort 7,000 (98)a UK Occupational exposure General
population




Cohort 292 (12)a USA Job history General
population
SMR total cohort = 347
(p = ns)





Case–control 1,037 (358) Utah, USA Diet >61 vs. < 36
lg/day




Nested case–control 6,995 (39) USA Job category Medium
vs. low
OR = 1.55 (0.49–4.93)
High vs. low OR = 1.35 (0.31–5.91)
Platz
et al. [67]
Nested case–control 342 (115) USA Toenailc 5th vs. 1st
quintile
OR = 0.70 (0.36–1.37)
Sorahan
et al. [60]




SMR = 127 (p < 0.05)
Kazantzis
et al. [63]




SMR = 90 (61–129)
a Number in parentheses represents number of deaths; b SMR = standardized mortality ratio; c Cd content determined using Flame
atomic absorption (FAA)
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arsenic levels in nails were outlined by Agahian et al. in
1990 [27], few epidemiologic studies have employed
this method. Garland et al. [24], using data from a
6-year reproducibility study, suggests that toenail
measures of zinc may be a good indicator of long-term
zinc exposure. In contrast, serum and plasma biomar-
kers of Zn are considered to be poor indicators of
whole body Zn status [28, 29] given that plasma levels
of zinc are homeostatically regulated and that other
common factors that can influence its distribution [29].
A detailed discussion of the validity/reproducibility of
biological specimens used for measuring trace element
exposure is beyond the scope of the present
review—more information can be found in the World
Health Organization’s (WHO) Trace Elements in
Human Nutrition and Health [2] and at the United
States Department of Health and Human Services
ATSDR website (described under the ToxFaq for each
trace element) http://www.atsdr.cdc.gov/toxfaq.html.
Results: trace elements and cancer risk—epidemiologic
evidence
Arsenic
Although there is some evidence of clinical manifes-
tations resulting from As deficiencies in certain animal
species [2, 30, 31], currently there is no known bene-
ficial biological function of As in humans. In contrast,
Table 6 Summary of epidemiologic studies of nickel (Ni) and cancer risk


















465 (213) Norway Job-exposure
matrix
>1.43 vs. 0 mg/m3-yr OR Sulfidic Ni = 1.2 (0.5–3.3)
>12.6 vs. 0 mg/m3-yr OROxidic Ni = 15 (0.4–2.5)






5,297 (267)a Norway Work history General population SMRc total Ni = 3.3 (2.8–3.8)




Cohort 522 (195)a Sweden Job history General population SMR = No association
Sorahan [62] Cohort 3,025 (102) United
Kingdom
Job history ‡ 15 vs. 0 yrs. exposed RR = No association
Karjalainen
et al. [80]
Cohort 1,388 (18) Finland Job exposure General population SIR Employed before 5/1/60 = 1.0
(0.4–1.9)
SIR Employed after 5/1/60 = 1.1
(0.5–2.0)
Pang et al. [81] Cohort (5)a United
Kingdom
Job history ‡ 1 vs. < 1 yrs. exposed RR = 1.25 (0.36–4.33)
Andersen
et al. [83]
Cohort 125,000 (203) Norway Job exposure ‡ 15 vs. 0 yrs. exposed SIR = 3.0 (2.6–3.4)
125,000 (55) RR soluble Ni = 3.1 (2.1–4.8)
d
RR Ni oxide = 1.5 (1.0–2.2)
d
Jarup et al. [82] Cohort 869 (16) Sweden Job exposure General population SMR = 176
Stomach
Pang et al. [81] Cohort (5)a United
Kingdom
Job history ‡1 vs. < 1 yrs. exposed RR = 2.61 (0.60–11.33)
Karjalainen
et al. [80]
Cohort 1,388 (12) Finland Job exposure General population SIR Employed before 5/1/60 = 1.8
(0.7–3.7)
SIR Employed after 5/1/60 = 1.3
(0.4–3.1)
Bladder









General population SMR = 127 (p < 0.05)
a Number in parentheses represents number of deaths; b SIR = standardized incidence ratio; c SMR = standardized mortality ratio;
d Statistically significant dose–response relationship reported
Cancer Causes Control (2007) 18:7–27 13
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As has been shown to induce carcinogenesis via a wide
range of cellular changes including alterations in cell
differentiation and proliferation [7, 32]. In addition,
inorganic As has been found to induce chromosomal
aberrations and sister chromatid exchange [7]. Cells
exposed to As have also been shown to increase cel-
lular tyrosine phosphorylation, which is related to the
aberrant cell signaling and uncontrolled cell growth
associated with cancer development [33, 34]. A review
of the As in drinking water was recently compiled by
the State of California [35] and provides information
on the association between As and other health con-
ditions, including cancer outcomes not included in this
review.
A number of ecologic studies from Taiwan, a loca-
tion known for its high levels of As in drinking water
(average intake > 1 mg/day [36]), have suggested that
As may be associated with increased risks of bladder
and lung cancer. Given this, studies of lung and bladder
cancer risk have been conducted in other areas with
known geologic As contamination of drinking water. A
summary of the literature regarding high levels of As
exposure (‡100 lg/l) and cancer risk is presented in
Table 3. Two case–control [37, 38] and two [39, 40] out
of three [39–41] cohort studies have found elevated
lung cancer risks associated with high levels of expo-
sure to As from drinking water, whereas one cohort
study showed an inverse association [41]. In addition,
case–control [37, 42] and four [39, 40, 43, 44] out of five
[39–41, 43, 44] cohort studies conducted in areas with
high As concentrations in drinking water have shown
positive associations between As in drinking water and
bladder cancer risk. Furthermore, there is some evi-
dence that exposure to high levels of As in drinking
water is associated with an increased risk of prostate
cancer [41].
While the association between As and cancer,
particularly lung and bladder cancers, is established at
high levels of exposure, the association at lower levels
(< 100 lg/l) is less certain. A summary of the literature
regarding lower levels of As exposure (both occupa-
tional and from drinking water) and cancer risk is
presented in Table 4. In the only study of As and
breast cancer risk reported to date, Garland et al. [45]
observed no association between levels measured in
toenails and risk. With respect to lung cancer, one
case–control [46] and two cohort studies [47, 48] have
observed positive associations between occupational
As exposure and lung cancer risk, while one case–
control study by Coggon et al. [49] found no associa-
tion between occupational As exposure and risk of
lung cancer. However, exposure in the latter study was
estimated by creating a job matrix where occupational
units were classified according to their likely exposure
to As rather than direct measurement of airborne
levels, and therefore the levels of exposure cannot be
directly compared to those in the other studies in-
cluded in this review [49]. Both Bates et al. [50] and
Steinmaus et al. [51], in analyses of As in drinking
water, and Michaud et al. [52], in an analysis of toenail
As, found no association between As exposure and
bladder cancer risk.
Cadmium
Although there is some evidence that low concentra-
tions of dietary Cd may be beneficial to some animal
species [2], currently there is no evidence of a benefi-
cial function in humans. Indeed, on the basis of evi-
dence from experimental and epidemiologic studies,
IARC [8] and the US National Toxicology Program
[53] have designated Cd as a known human carcinogen.
It is thought that Cd acts via genotoxic mechanisms
including induction of single-strand DNA breaks [54],
and also that it inhibits DNA repair by inactivation of
the mismatch repair system [54, 55], activates proto-
oncogenes [56, 57] and inhibits apoptosis [58].
Table 5 presents a summary of the literature
regarding Cd exposure and cancer risk. To date, most
studies of Cd and cancer have focused on lung and
prostate cancer. Six of the seven occupational cohort
studies that have been reported have found statistically
significant increased risks of lung cancer associated
with relatively high Cd exposure [59–65].
The relationship between Cd exposure and prostate
cancer risk has been examined in one case–control [66],
two nested case–control [67, 68], and two cohort
analyses [60, 63]. In the only case–control study to date
(358 incident cases), West et al. [66] reported a statis-
tically significant positive association with ingested Cd
from dietary sources, as assessed by a food frequency
questionnaire. The remaining studies differed in that
they examined the association between occupational
Cd exposure and prostate cancer risk. Armstrong and
Kazantzis [68] and Platz et al. [67] each analyzed data
from two separate US cohort studies using nested case–
control designs (39 and 115 incident cases, respec-
tively) and reported no association between high Cd
exposure and prostate cancer risk. Kazantzis et al. [63]
likewise found no association between occupational
exposure to Cd and prostate cancer mortality in a
British cohort, but the study included only 30 cases. In
contrast, Sorahan and Watherhouse [60] observed a
statistically significant increased risk of prostate cancer
mortality among Ni–Cd alloy workers in the United
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Kingdom, although this finding was based on only five
prostate cancer cases.
Nickel
In 1996, the World Health Organization classified Ni
as a trace element that is ‘probably’ essential [2], given
its role in Ni-containing enzymes found in plants and
microorganisms. However, evidence that Ni has simi-
lar functions in humans is not currently available. In
contrast, Ni compounds can display tumor promoting
capability via a number of mechanisms including
inhibition of intercellular communication [69],
immortalization of fibroblasts and epithelial cells
[70–73], the induction of DNA deletions and aberra-
tions [74], production of DNA-protein cross-links,
oxidative damage, inhibition of nucleotide excision
repair [74–76] and an increase in DNA methylation
leading to inactivation of gene expression [77]. In ep-
idemiologic studies of the association between Ni and
cancer risk, Ni has been examined either alone or in
combination with Cd (in the form of Ni–Cd) (Table 6).
Grimsrud et al. [78], in a nested case–control study
of Norwegian Ni-refinery workers, reported no
association between lung cancer incidence and occu-
pational sulfidic, oxidic, or metallic Ni exposure.
However, in a subsequent study based on the same
cohort, Grimsrud et al. [79] analyzed data for workers
employed between 1910 and 1989 and who were alive
after 1953, and they reported an increased risk of lung
cancer associated with both total and water-soluble Ni
after controlling for smoking history. Of the six cohort
studies of job-related Ni exposure, four observed no
association with lung cancer risk [61, 62, 80, 81], and
two observed an increased risk [82, 83] (Table 6).
Studies of colorectal, bladder, and gastric cancers
[80, 81] and Ni exposure have also been conducted and
have reported no association (Table 6). In contrast,
Sorahan and Watherhouse [60] reported a statistically
significant increased risk of prostate cancer mortality
with relatively high occupational Ni exposure. As with
results for other cancer sites, the conclusions that can
be drawn from these studies are limited by the rela-
tively small number of cases included (Table 6).
Selenium
Selenium is considered an essential trace element
because it is the primary component of selenoproteins,
which have roles in counteracting oxidative stress and
regulating the redox status of other molecules [84].
Not surprisingly, therefore, Se has been studied
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preventive effects. While there is epidemiologic evi-
dence to support an inverse association between Se and
risk of some cancers, the evidence is not consistent. A
summary of the current literature regarding Se expo-
sure and risk of breast, colorectal, lung, stomach,
bladder, and prostate cancer is presented in Table 7.
The results of case–control and prospective cohort
studies conducted to date do not support an association
between Se and breast cancer [23, 85–94]. Of the seven
case–control studies [23, 85–87, 91, 93, 94], only
Schrauzer et al. [93] found a statistically significant
inverse association between Se exposure and breast
cancer risk. In contrast, larger case–control studies
such as those by Van’t Veer et al. [85, 86] and
Ghadirian et al. [87], both of which examined toenail
Se, which is considered more representative of long-
term Se exposure [95, 96], found no association with
breast cancer risk. In addition, none of the four cohort
studies that have examined this relationship [88–90,
92], of which three utilized toenail measures of Se
exposure [88–90], have found any association between
Se and breast cancer risk. The conclusion that Se is not
associated with breast cancer risk is supported by the
fact that studies to date have measured exposure using
different approaches (including analysis of toenail,
whole blood, plasma, and erythrocyte samples, and
measurement of dietary Se), and produced mostly null
results. In this regard, van’t Veer et al. [85] examined
the association between Se and breast cancer risk by
measuring both dietary Se intake using a FFQ and Se
concentrations in plasma, erythrocytes, and toenails.
The magnitude of the odds ratios comparing extreme
quartile levels ranged from 0.9 (erythrocyte Se) to 2.0
(plasma Se), and none of these associations was
statistically significant [85].
In a cross-sectional study of 48 individuals in
the United States, Clark et al. [97] observed an almost
4-fold increased risk of colorectal cancer for plasma Se
concentrations ‡ 128 lg/l versus those < 128 lg/l
(95% CI = 1.02–15.71). However, subsequent case–
control and cohort studies of Se and colorectal cancer
risk, using either serum [98–100] or toenails [87, 101–
103] for Se measurement, have largely reported no
association [87, 99–103]. Fernandes-Banares et al. [98]
used fasting blood samples and showed an inverse
association between serum Se levels and risk, while
Nomura et al. [99] used non-fasting samples and
showed no association with serum Se levels. However,
given that Se levels measured in blood samples repre-
sent recent exposure, comparison of the results of
studies using fasting blood samples to those using
non-fasting blood samples may not be appropriate.
Furthermore, long-term measures of Se intake are
more useful. In this regard, Ghadirian et al. [87],
Mannisto et al. [102], van den Brandt et al. [103], and
Garland et al. [101] measured Se concentrations in
toenail samples, each using similar methodologies.
However, the results were mixed, with Ghadirian et al.
[87] reporting a statistically significant inverse associ-
ation, Mannisto et al. [102] and van den Brandt et al.
[103] observing no association, and Garland et al. [101]
reporting a statistically non-significant increased risk of
colorectal cancer.
Results from nested case–control studies of Se and
lung cancer risk have been mixed. Kabuto et al. [104]
conducted a nested case–control study in Japan and
reported that cases were more likely to have higher
serum Se concentrations than controls, while Nomura
et al. [99] and Ratnasinghe et al. [105], in nested case–
control analyses of data from Hawaii and China,
respectively, reported no association with serum levels.
More recently, a randomized trial was conducted in the
United States to test the effect of Se supplementation
(200 lg/day) on non-melanoma skin cancer recurrence,
with lung cancer incidence as a secondary endpoint
[106]. Although analysis of data from the first 10 years
of the study (1983–1993) revealed a 44% decrease in
lung cancer risk (95% CI = 0.31–0.76) in association
with the intervention [106], a re-analysis conducted
after three years of additional follow-up revealed
attenuation of the hazard ratio to 0.74, which was no
longer statistically significant (95% CI = 0.44–1.24). A
limitation of this study is that it included only 60 inci-
dent lung cancer cases [106]. In addition to these
studies, which assessed Se exposure using serum
samples, toenail Se levels have been investigated in
relation to lung cancer risk in a number of studies.
Hartman et al. [107], in a nested case–control analysis
of data from the Alpha-Tocopherol Beta-Carotene
(ATBC) Cancer Prevention Cohort based on 250
cases, found a statistically significant inverse associa-
tion between toenail Se and risk. Likewise, van den
Brandt et al. [108] reported a 50% decreased risk of
lung cancer associated with toenail Se concentrations
(ptrend = 0.0006). In contrast, Garland et al. [101], in
an analysis of data from the Nurses’ Health Study
(47 incident cases), reported an approximately 4-fold
increased risk of lung cancer, although this finding was
not statistically significant.
The results of studies of the association between Se
and gastric cancer risk have varied somewhat, although
most have yielded point estimates at or below unity.
Ecologic studies conducted in Japan [109] and China
[110] showed statistically significant inverse correla-
tions between Se in drinking water and plasma Se,
respectively, and gastric cancer mortality. Chen et al.
18 Cancer Causes Control (2007) 18:7–27
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[111] in a cross-sectional study and Kabuto et al. [104],
in a case–control study, however, observed no associ-
ation between serum Se and stomach cancer risk.
Likewise, both Zhang et al. [112] and Nomura et al.
[99] observed no association between serum Se and
stomach cancer risk in nested case–control studies in
the United States. In contrast, three of four case-cohort
studies have reported statistically significant inverse
associations [103, 113–115]. Two randomized trials of
dietary supplementation have been conducted in
Linxian, China [116, 117], a region known for both its
high incidence of gastric cancer and a number of
nutritional deficiencies [114]. The larger General
Population Trial, which included 29,584 adults (16
incident cases) found no association with the vitamin
E/b-carotene/Se combination [117]. Dawsey et al. [116]
analyzed data from the Dysplasia Trial in Linxian,
China, and at the 1987 follow-up they found an in-
creased risk of gastric cancer in association with a
multivitamin, multimineral supplement containing Se,
but an inverse association in 1991; neither of these
findings was statistically significant. However, given
that these trials examined the effect of Se in concert
with other vitamins/minerals, conclusions about the
effect of Se supplementation alone cannot be drawn
from them.
With respect to bladder cancer, Nomura et al. [99]
and Helzlsouer et al. [118] each examined the associ-
ation between serum Se and risk and reported elevated
odds ratios (1.9 and 2.06, respectively) for the lowest
versus the highest tertile of serum Se. While neither of
these associations was statistically significant,
Helzlsouer et al. [118] did report a statistically signifi-
cant trend (ptrend = 0.03) of increasing risk with
decreasing serum Se levels. Similarly, Zeegers et al.
[119] reported an inverse association between toenail
Se concentration and bladder cancer risk in a case-
cohort analysis from the Netherlands Cohort Study.
Michaud et al. [120], however, found no association
between toenail Se and bladder cancer in a nested
case–control analysis of male smokers enrolled in the
Alpha-Tocopherol/Beta-Carotene (ATBC) trial. Cur-
rently there is insufficient evidence to draw a conclu-
sion regarding the association between Se exposure
and bladder cancer risk.
Recently, much attention has been given to the
potentially protective effect of Se in relation to pros-
tate cancer. In this regard, although a number of case–
control studies, nested [92, 94, 113], and non-nested
[87, 121, 122], have suggested that there is no associa-
tion between Se and prostate cancer risk, several other
nested case–control analyses of data from different
study populations within the United States [123–127]
and a case-cohort analysis of data from the Nether-
lands [128] have reported statistically significant in-
verse associations between Se concentrations (based
on measurements in plasma [123, 127], serum [125]
and/or toenails [124, 126, 128]) and prostate cancer
risk. Hartman et al. [129] analyzed data from the
ATBC trial as a cohort study and reported that dietary
Se (both including and excluding supplements) was not
associated with prostate cancer risk, although there
was some evidence for an inverse association with Se
among those receiving a-tocopherol supplements.
Randomized trials have also been undertaken to
further study the potential association between Se and
prostate cancer risk. In one such study, Clark et al.
[130] examined data from a trial conducted in the
United States and reported a 63% decreased risk of
prostate cancer for those receiving 200 lg of Se per day
versus placebo after 4.5 years of treatment and
6.5 years of follow up (ptrend = 0.002). The Selenium
and Vitamin E Cancer Prevention Trial (SELECT), a
clinical trial with more than 35,000 participants, which
will take approximately 12 years to complete, was
initiated in order to further investigate this association
(http://cancer.gov/select).
Zinc
The effects of Zn deficiency in humans were first
reported in the 1960s [131, 132] and include growth
retardation, cognitive impairment and immune
dysfunction [133]. Zinc is also involved with metallo-
thionine synthesis, which is thought to inhibit free
radical production [134]. Furthermore, it has been
shown that zinc chloride significantly decreases DNA
strand breaks in human cutaneous fibroblasts exposed
to UVA1 radiation [135]. Hence, it is conceivable that
there might be an inverse association between Zn and
cancer risk.
The association between Zn levels and cancer risk
has been examined for several anatomic sites
(Table 8]. Case–control studies by Gupta et al. [136]
(35 cases), and more recently by Adzersen et al. [137]
(310 cases), both yielded statistically significant inverse
associations between Zn exposure, measured in serum
and diet, respectively, and breast cancer risk. Garland
et al. [45], however, in a nested case–control study,
including 433 incident cases, reported no association
between toenail Zn and breast cancer risk. Whole
blood, and its components, can be tested to measure
exposure to a number of trace elements. Plasma and
serum measures tend to reflect short-term exposures,
while trace element levels in erythrocytes represent
long-term exposure [23]. As noted earlier, there is
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evidence that status biomarkers such as blood and
plasma tend to be poor indicators of whole body Zn
status [28]. Toenails are often preferable to other
biological samples (e.g., blood, urine) for the mea-
surement of trace element levels because they tend to
reflect longer-term exposure. The use of different
status biomarkers in these studies may be an important
contributor to the mixed outcome results of competing
studies.
The literature regarding the association between Zn
exposure and lung cancer differs according to the level
of Zn exposure. That is, when compared to those who
are Zn sufficient, the effect of Zn deficiency is different
from that of Zn overexposure (e.g, through occupa-
tional exposure). A case–control study by Sattar et al.
[5], which compared individuals who were Zn deficient
as a result of inadequate dietary intake to those who
were Zn sufficient, suggested that there is an inverse
association between plasma Zn levels and lung cancer
risk, while in other studies of Zn deficiency, both
Harris et al. [138] and Kabuto et al. [104] found no
association with lung cancer risk. The results of studies
of occupational Zn exposure are mixed. A case–control
study by Blot et al. [6], which compared individuals
who are Zn sufficient to those who have Zn overload,
found a positive association between occupational Zn
exposure and risk. In contrast, Cocco et al. [139], in a
prospective study of 4,740 lead and Zn smelter workers
in Italy, found no association between lung cancer
mortality and airborne Zn concentrations as assessed
using regular measurements of airborne dust from
personal and static sampling devices.
Zinc has also been examined in association with risk
of gastric cancer. In a case–control study, Zhang et al.
[140] utilized a FFQ to determine dietary Zn intake
and reported an inverse trend of borderline statistical
significance with increasing consumption
(ptrend = 0.07). In contrast, Kabuto et al. [104] com-
pared serum Zn concentrations in cases of gastric
cancer (77 incident cases) and controls in Japan and
observed essentially no difference. Zhang et al. [112]
likewise observed no difference in the Zn:Cu ratio
between cases and controls in a nested case–control
study in the United States (88 incident cases). Analyses
of data from two randomized trials conducted in China
have found no association between a combination of
supplements, including Zn (22.5 mg and 45 mg,
respectively), and gastric cancer risk [116, 117].
A number of studies have also been undertaken to
examine the association of Zn with prostate cancer.
Studies comparing Zn levels in malignant to normal
prostate tissue have found that Zn is 60–70% lower in
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results from case–control and cohort studies have been
mixed. Kolonel et al. [142] studied the association be-
tween dietary Zn intake and risk, stratified by age, and
reported a statistically significant positive association
between total Zn (including Zn from foods and
supplements) and prostate cancer risk among Hawai-
ian men 70 years of age and older, but found no
association between either total dietary Zn or non-
supplemental Zn and risk among men under 70 years
of age, while Leitzmann et al. [143] found a 2.9-fold
increased risk of advanced prostate cancer with sup-
plemental Zn use in a prospective cohort study con-
ducted in the United States.. In contrast, Kristal et al.
[144] found a borderline inverse association between
frequency of Zn supplement use and prostate cancer
risk in a case–control study in the United States, and
recently, Platz et al. [67] conducted a nested case–
control study of prediagnostic toenail Zn and found a
statistically non-significant 37% decreased risk of
prostate cancer in association with toenail Zn levels. In
case–control studies in Utah and Yugoslavia, respec-
tively, neither West et al. [66] nor Vlajinac et al. [145]




There is now a substantial body of epidemiologic lit-
erature on the association between trace element
exposure and cancer risk and a summary of the current
state of the evidence for the cancer sites of interest here
is presented in Table 9. In drawing our conclusions, we
considered issues related to exposure measurement,
study design, and sample size. Results from cohort
studies and randomized trials (when available) were
given greater consideration than were results from
case–control and cross-sectional studies on the same
topic. In addition, studies which utilized objective
exposure measures (e.g., biological measures) were gi-
ven more weight than were those that used subjective
measures (e.g., qualitative assessments of high/medium/
low exposures).
In brief, the evidence currently available appears to
support an inverse association between Se exposure
and prostate cancer risk. In contrast, the vast majority
of the studies of Se and breast cancer, which have
included large case–control and cohort studies utilizing
different means of quantifying exposure, do not appear
to support an association. Similarly, there do not
appear to be associations between Se and risk of
colorectal or stomach cancer. With respect to Zn, al-
though there is literature from case–control studies to
support an inverse association between Zn and breast
cancer risk, the one cohort study to date does not
support an association and additional prospective
studies are needed. To date, there is essentially no
evidence for associations between dietary Zn intake
and risk of stomach or prostate cancer, or between
occupational Zn exposure and lung cancer risk. There
is compelling evidence to support positive associations
between As and risk of lung cancer at both high and
low exposure levels and between As and bladder
cancer risk at high exposure levels [35]. There is also
strong evidence of a positive association between
occupational Cd exposure and lung cancer risk.
Future directions
Although the association between trace element
exposure and cancer risk has been examined in a
number of large prospective studies, there is a need for
Table 9 Summary of findings from epidemiological studies
Trace element Cancer site
Breast Colorectal Lung Stomach Bladder Prostate
Arsenic
High level NA NA Positive More studies
needed
Positive More studies needed
Low level More studies
needed
NA Positive NA More studies
needed
NA












Selenium No association No association Possible inverse No association Mixed Inverse
Zinc More studies
needed
NA No association No association NA No association
NA = No studies available
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a larger studies to be conducted to enable the possi-
bility of effect modification to be examined. For
example, it would be of interest to examine the asso-
ciation between Zn and other trace elements and lung
cancer risk across strata of smoking history due to the
antioxidant role of Zn.
While randomized trials of Se have been conducted
with respect to stomach cancer and have been initiated
to assess its effect on risk of prostate cancer, random-
ized trials investigating other trace elements that may
also reduce cancer risk (e.g., Zn) have not been con-
ducted as yet. Such trials might focus initially on the
effect of the interventions on intermediate end-points
such as cancer precursors.
Finally, while there is now a considerable amount of
epidemiologic evidence concerning the role of trace
elements in influencing cancer risk, additional studies
are needed to elucidate further the mechanisms
underlying trace element carcinogenesis.
Appendix 1
Search strategy employed for each of the cancers of
interest in Medline
Cancer of interest Search terms
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